Folic acid : a potential inhibitor against SARS-CoV-2 nucleocapsid protein
CONTEXT: Coronavirus disease 2019 is a global pandemic. Studies suggest that folic acid has antiviral effects. Molecular docking shown that folic acid can act on SARS-CoV-2 Nucleocapsid Phosphoprotein (SARS-CoV-2 N).
OBJECTIVE: To identify novel molecular therapeutic targets for SARS-CoV-2.
MATERIALS AND METHODS: Traditional Chinese medicine targets and virus-related genes were identified with network pharmacology and big data analysis. Folic acid was singled out by molecular docking, and its potential target SARS-CoV-2 N was identified. Inhibition of SARS-CoV-2 N of folic acid was verified at the cellular level.
RESULTS: In total, 8355 drug targets were potentially involved in the inhibition of SARS-CoV-2. 113 hub genes were screened by further association analysis between targets and virus-related genes. The hub genes related compounds were analysed and folic acid was screened as a potential new drug. Moreover, molecular docking showed folic acid could target on SARS-CoV-2 N which inhibits host RNA interference (RNAi). Therefore, this study was based on RNAi to verify whether folic acid antagonises SARS-CoV-2 N. Cell-based experiments shown that RNAi decreased mCherry expression by 81.7% (p < 0.001). This effect was decreased by 8.0% in the presence of SARS-CoV-2 N, indicating that SARS-CoV-2 N inhibits RNAi. With increasing of folic acid concentration, mCherry expression decreased, indicating that folic acid antagonises the regulatory effect of SARS-CoV-2 N on host RNAi.
DISCUSSION AND CONCLUSIONS: Folic acid may be an antagonist of SARS-CoV-2 N, but its effect on viruses unclear. In future, the mechanisms of action of folic acid against SARS-CoV-2 N should be studied.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:60 |
|---|---|
| Enthalten in: |
Pharmaceutical biology - 60(2022), 1 vom: 21. Dez., Seite 862-878 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chen, Yu-Meng [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
935E97BOY8 |
|---|
| Anmerkungen: |
Date Completed 24.05.2022 Date Revised 07.12.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1080/13880209.2022.2063341 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM341169919 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM341169919 | ||
| 003 | DE-627 | ||
| 005 | 20231226011148.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/13880209.2022.2063341 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1137.xml |
| 035 | |a (DE-627)NLM341169919 | ||
| 035 | |a (NLM)35594385 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chen, Yu-Meng |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Folic acid |b a potential inhibitor against SARS-CoV-2 nucleocapsid protein |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.05.2022 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a CONTEXT: Coronavirus disease 2019 is a global pandemic. Studies suggest that folic acid has antiviral effects. Molecular docking shown that folic acid can act on SARS-CoV-2 Nucleocapsid Phosphoprotein (SARS-CoV-2 N) | ||
| 520 | |a OBJECTIVE: To identify novel molecular therapeutic targets for SARS-CoV-2 | ||
| 520 | |a MATERIALS AND METHODS: Traditional Chinese medicine targets and virus-related genes were identified with network pharmacology and big data analysis. Folic acid was singled out by molecular docking, and its potential target SARS-CoV-2 N was identified. Inhibition of SARS-CoV-2 N of folic acid was verified at the cellular level | ||
| 520 | |a RESULTS: In total, 8355 drug targets were potentially involved in the inhibition of SARS-CoV-2. 113 hub genes were screened by further association analysis between targets and virus-related genes. The hub genes related compounds were analysed and folic acid was screened as a potential new drug. Moreover, molecular docking showed folic acid could target on SARS-CoV-2 N which inhibits host RNA interference (RNAi). Therefore, this study was based on RNAi to verify whether folic acid antagonises SARS-CoV-2 N. Cell-based experiments shown that RNAi decreased mCherry expression by 81.7% (p < 0.001). This effect was decreased by 8.0% in the presence of SARS-CoV-2 N, indicating that SARS-CoV-2 N inhibits RNAi. With increasing of folic acid concentration, mCherry expression decreased, indicating that folic acid antagonises the regulatory effect of SARS-CoV-2 N on host RNAi | ||
| 520 | |a DISCUSSION AND CONCLUSIONS: Folic acid may be an antagonist of SARS-CoV-2 N, but its effect on viruses unclear. In future, the mechanisms of action of folic acid against SARS-CoV-2 N should be studied | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Chinese medicine | |
| 650 | 4 | |a antivirus | |
| 650 | 4 | |a network pharmacology | |
| 650 | 7 | |a Coronavirus Nucleocapsid Proteins |2 NLM | |
| 650 | 7 | |a Phosphoproteins |2 NLM | |
| 650 | 7 | |a nucleocapsid phosphoprotein, SARS-CoV-2 |2 NLM | |
| 650 | 7 | |a Folic Acid |2 NLM | |
| 650 | 7 | |a 935E97BOY8 |2 NLM | |
| 700 | 1 | |a Wei, Jin-Lai |e verfasserin |4 aut | |
| 700 | 1 | |a Qin, Rui-Si |e verfasserin |4 aut | |
| 700 | 1 | |a Hou, Jin-Ping |e verfasserin |4 aut | |
| 700 | 1 | |a Zang, Guang-Chao |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Guang-Yuan |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Ting-Ting |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pharmaceutical biology |d 1997 |g 60(2022), 1 vom: 21. Dez., Seite 862-878 |w (DE-627)NLM097504416 |x 1744-5116 |7 nnns |
| 773 | 1 | 8 | |g volume:60 |g year:2022 |g number:1 |g day:21 |g month:12 |g pages:862-878 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/13880209.2022.2063341 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 60 |j 2022 |e 1 |b 21 |c 12 |h 862-878 | ||